Onconova, a privately held Delaware Corporation, is developing innovative products for combating cancer. We are creating novel Solutions for Oncology by combining conventional pharmaceutical science (a small molecule approach) with the latest genomic and genetic technologies for drug discovery and development.

Anticipated Milestones

Phase II and proof of concept in Q4-2008.

Advance of lead compound to full development leading to an IND submission in 2008.

ON 013105 for Mantle Cell Lymphoma - IND in Q4-2008.

Human testing in 2008 leading to expedited approval of Ex-RAD™ is expected. This program is developed under Animal Rule.

read more